GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (FRA:XRP2) » Definitions » Shiller PE Ratio

Silence Therapeutics (FRA:XRP2) Shiller PE Ratio : (As of Jun. 13, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Silence Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Silence Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Shiller PE Ratio Chart

Silence Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Silence Therapeutics Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Silence Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Silence Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Shiller PE Ratio falls into.



Silence Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Silence Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Silence Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.049/131.6000*131.6000
=-0.049

Current CPI (Mar. 2024) = 131.6000.

Silence Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200806 -7.750 86.600 -11.777
200812 -3.480 87.100 -5.258
200906 -4.663 88.100 -6.965
200912 -4.911 88.900 -7.270
201006 -4.567 90.200 -6.663
201012 -1.203 91.700 -1.726
201106 -1.637 93.500 -2.304
201112 -0.408 95.000 -0.565
201206 -7.623 95.600 -10.494
201212 2.640 97.300 3.571
201306 -0.296 98.000 -0.397
201312 -0.416 99.200 -0.552
201406 -0.430 99.800 -0.567
201412 -0.400 99.900 -0.527
201506 -0.296 100.100 -0.389
201512 -0.136 100.400 -0.178
201606 -0.258 101.000 -0.336
201612 -0.188 102.200 -0.242
201706 -0.270 103.500 -0.343
201712 0.190 105.000 0.238
201806 -0.423 105.900 -0.526
201812 -0.461 107.100 -0.566
201906 -0.387 107.900 -0.472
201912 -0.407 108.500 -0.494
202006 -0.457 108.800 -0.553
202009 -0.363 109.200 -0.437
202012 -0.500 109.400 -0.601
202103 -0.339 109.700 -0.407
202106 -0.457 111.400 -0.540
202109 -0.389 112.400 -0.455
202112 -0.371 114.700 -0.426
202203 -0.309 116.500 -0.349
202206 -0.465 120.500 -0.508
202209 -0.247 122.300 -0.266
202212 -0.452 125.300 -0.475
202303 -0.323 126.800 -0.335
202306 -0.336 129.400 -0.342
202309 -0.257 130.100 -0.260
202312 -0.435 130.500 -0.439
202403 -0.049 131.600 -0.049

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Silence Therapeutics  (FRA:XRP2) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Silence Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Silence Therapeutics (FRA:XRP2) Business Description

Traded in Other Exchanges
Address
72 Hammersmith Road, London, GBR, W14 8TH
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

Silence Therapeutics (FRA:XRP2) Headlines

No Headlines